Skip to main content

Day: June 28, 2020

미국국립의료원 (NIH), 엠마우스생명과학에 독점 특허 라이센스 부여

캘리포니아주 토랜스, June 29, 2020 (GLOBE NEWSWIRE) — 겸상적혈구질환 치료의 선두주자 엠마우스생명과학 (“엠마우스”, OTCQB: EMMA)은 2020년 06월 22일, 미국보건복지부, 국립보건원 산하, 국립암연구소에서 엠마우스생명과학의 자회사인 엠마우스메디컬에게 통지의 보충섹션에 나열된 특허출원 및 특허에서 구현된 발명을 발명을 실시하기 위한 독점 특허 라이선스를 부여할 계획이라고 통지하고 오늘 밝혔습니다. 통지는 다음의 링크에서 액세스 할 수 있습니다: https://bit.ly/3erJfZz. 일반국민들은 제안된 보조금에 대하여 2020년 07월 07일까지 의견을 표시하여야 합니다. 제안된 라이선스의 조건은 공개되지 않았습니다.이 특허기술은 국부투여를 위하여 백색와셀린, 미네랄오일 및 비사보롤에 분산되어 있는 0.5%에서 3.0% 중량의 비산성화된 아질산나트륨을 포함하는 연고제제입니다. 아질산염 음이온은 산소장력과 pH가 낮은 조직에서 산화질소를 생성함으로써 생체 내 혈관확장제의 역할을 할 수 있습니다. 이런 제형을 통한 아질산나트륨의 치료적 적용은 겸상적혈구질환 및 2 형 당뇨병을 포함하여 여러질환관 관련된 만선허혈성 및 신경병질의 궤양과 관련성이 있는 궤양을 치료하는 저산소 조직에 선택적 혈관확장을 제공할 수 있습니다.“혁신적이고 새로운 치료법을 발견하기 위해 노력하는 미국국립의료원 및 재능 있는 발명가들과 일할 수 있게 되어 매우 기쁩니다. 피부궤양은 겸상적혈구질환의 중증, 만성 및 재발성 합병증입니다. 우리는 겸상적혈구질환 및 당뇨병과 같은 다른 질병과 관련된 피부궤양을 치료하기 위하여 이런 유망한 치료법을 개발하기를 기대합니다.”라고 엠마우스의...

Continue reading

Staffing 360 Solutions Reports First Quarter 2020 Results

Pandemic-Impacted Revenue Slowly ImprovingNEW YORK, June 26, 2020 (GLOBE NEWSWIRE) — Staffing 360 Solutions, Inc. (NASDAQ: STAF), a company executing an international buy-integrate-build strategy through the acquisition of staffing organizations in the United States and the United Kingdom, today announced Fiscal 2020 first quarter results, which were impacted in March by the economic downturn resulting from the COVID-19 pandemic.Brendan Flood, Chairman and Chief Executive Officer said, “Q1 results were directly in line with the guidance provided in our year-end financial results call. As anticipated, the revenue decline was principally due to the loss of a low-margin client in the UK and the impact of IR35 payroll tax legislation in the UK.  Additionally, late in the quarter both countries in which we do business were negatively...

Continue reading

Results of Operations for the Year Ended December 31, 2019 – American Overseas Group Limited Announces Net Loss Of $3.7 Million and Operating Loss of $9.1 Million For the Year Ended December 31, 2019

HAMILTON, Bermuda, June 26, 2020 (GLOBE NEWSWIRE) — American Overseas Group Limited (BSX: AORE.BH) (Pink Sheets: AOREF.PK) (“AOG” or the “Company”) today reported consolidated net loss available to common shareholders of $3.7 million, or $80.13 per diluted share, for the year ended December 31, 2019. This compares to consolidated net loss available to common shareholders of $3.2 million, or $69.12 per diluted share, for the year ended December 31, 2018.The results for the year were driven by losses in the Company’s financial guaranty segment related to commuted policies and Puerto Rico related credits. Book value per share at December 31, 2019 was $1,159.08, a decline from the book value per share of $1,212.83 at December 31, 2018. For the year ended December 31, 2019, the Company had an operating loss of $9.1 million, or $196.78...

Continue reading

Brattle Street Investment Releases Audited Financial Statements for Year Ended February 29, 2020

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.NEW YORK, June 26, 2020 (GLOBE NEWSWIRE) — Brattle Street Investment Corp. (“Brattle” or the “Company”) (TSXV:BRTL), today posted its audited financial statements for the year ending February 29, 2020. At year-end, the company’s audited balance sheet had a total of $9,192,643 in liquid assets, comprised of cash ($8,349,422) and marketable securities ($843,221), which is approximately $0.20 per share.The Company continues to seek opportunities that provide attractive returns relative to risk. Before the COVID-19 pandemic, the Company began pursuing a specific transaction. The Company recently devoted significant resources towards pursing the transaction, but management ultimately terminated negotiations when the arm’s length seller was...

Continue reading

Knight Therapeutics Reports First Quarter 2020 Results

MONTREAL, June 26, 2020 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2020. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified.Q1 2020 Highlights

Continue reading

Thérapeutique Knight publie ses résultats du premier trimestre 2020 

MONTRÉAL, 26 juin 2020 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société »), société pharmaceutique spécialisée panaméricaine (ex-ÉU) et chef de file, a publié aujourd’hui ses résultats financiers du premier trimestre clos le 31 mars 2020. Tous les montants sont exprimés en milliers à l’exception du nombre d’actions et des montants par action. Toutes les monnaies sont canadiennes, sauf indication contraire.Faits saillants du T1 20

Continue reading

Philips’ General Meeting of Shareholders approves dividend proposal

June 26, 2020Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Extraordinary General Meeting of Shareholders (EGM) approved the proposal to declare a distribution of EUR 0.85 per common share against the net income for 2019, in shares only.The dividend timetable is as follows:The number of share dividend rights entitled to one new common share will be determined based on the volume-weighted average price of all traded common shares of Koninklijke Philips N.V. at Euronext Amsterdam on June 30, and July 1 and 2, 2020. The company will calculate the number of share dividend rights entitled to one new common share, such that the gross dividend in shares will be approximately equal to EUR 0.85.For more information about Philips’ EGM, which was held today in Amsterdam, please click on this link.For further...

Continue reading

Euro Manganese to File Chvaletice Manganese Project Environmental Impact Assessment Notification

Filing of EIA Notification triggers project permitting processStudies confirm that Project is not expected to cause any significant adverse impacts to the environmental or human healthProject is designed to meet all Czech Republic and European Union environmental, health and safety standardsProject poised to become Europe’s only primary producer of high-purity manganese products by reprocessing waste, serving rapidly emerging European EV battery marketVANCOUVER, British Columbia, June 28, 2020 (GLOBE NEWSWIRE) — Euro Manganese Inc. (TSX-V / ASX: EMN) (“EMN” or the “Company”) is pleased to announce that it will file the Environmental Impact Assessment (EIA) Notification with the Czech Ministry of Environment on June 30th 2020, for its Chvaletice Manganese Project (“Chvaletice” or “the Project”) located in the Czech Republic....

Continue reading

Make Hero FinCorp Online EMI Payment With Ease

The advances in technology have made it possible for individuals to manage banking from the comfort of the home. Due to the lockdown and the current situation in the country, it might not be possible for you to step out of your house to make payments. However, this does not mean that you need to default in the EMI payment. If you have borrowed money, you can easily and conveniently make the EMI payment from home. Hero FinCorp online EMI payment allows you to ensure regular and timely payment of dues from anywhere in the world. Irrespective of the type of loan you have or the amount of loan outstanding, you can make the EMI payment with ease and convenience. All you have to do is transfer the money from your account to the account of the lender. You can also set up an auto debit. This works best for those who always maintain adequate funds...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.